PT - JOURNAL ARTICLE AU - Nogawa, Shun AU - Kanamori, Hajime AU - Tokuda, Koichi AU - Kawafune, Kaoru AU - Chijiiwa, Miyuki AU - Saito, Kenji AU - Takahashi, Shoko TI - Identification of susceptibility loci for adverse events following COVID-19 vaccination in the Japanese population: A web-based genome-wide association study AID - 10.1101/2021.11.30.21267043 DP - 2021 Jan 01 TA - medRxiv PG - 2021.11.30.21267043 4099 - http://medrxiv.org/content/early/2021/11/30/2021.11.30.21267043.short 4100 - http://medrxiv.org/content/early/2021/11/30/2021.11.30.21267043.full AB - The novel coronavirus disease 2019 (COVID-19) pandemic has spread rapidly worldwide. To prevent the spread of COVID-19, mRNA-based vaccines made by Pfizer/BioNTech (BNT162b1) and Moderna (mRNA-1273) have been widely used worldwide, including in Japan. Various adverse events after COVID-19 mRNA vaccinations have been reported, with differences observed among individuals. However, the analysis on the genetic background for susceptibility to side effects has been limited. In the present work, we performed genome-wide association studies (GWAS) for self-reported adverse events of COVID-19 mRNA vaccination in 4,545 Japanese individuals and identified 14 associated loci. Among these, 6p21 was associated with 37.5°C or higher fever, 38 °C or higher fever, and muscle pain. Our results may enable one to prepare for and manage side effects by knowing their susceptibility to the occurrence of adverse events. Furthermore, we obtained valuable data that can lead to the understanding of the mechanism of action of COVID-19 mRNA vaccines.Competing Interest StatementS.N., K.K, and M.C. are employees of Genequest Inc.; K.S. and S.T. are board members of Genequest Inc.; H.K. and K.T. declare no competing interests.Funding StatementThis work was supported by internal funding from Genequest, Inc.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Ethics Committee of Genequest Inc. (IRB no. 2021-0633-4) and Tohoku University Graduate School of Medicine (IRB no. 2021-1-469).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data analyzed during this study are included in this published article and its additional files. Other data are available from the authors upon reasonable request.